‘. VISTA-16 basis an innovative approach to years of extensive study of the adverse effects of inflammation in patients with ACS represents, ‘said Stephen J. Nicholls, director of the cardiovascular – C5 research at the Cleveland clinic and Chairman of the VISTA-16 Executive Committee. ‘We are thrilled that our efforts to promote this promising therapeutic. ‘.

2005 Rush University Medical Center, Chicago, Illinois?once daily successfully Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review Of Varespladib MethylAnthera Pharmaceuticals , a biopharmaceutical company to deal with, the drug cause serious diseases with inflammation, that the entry in the VISTA-16 phase 3 study varespladib in Acute Coronary Syndrome will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data..The cytotoxic DACH platinum to cancer ‘This template a major milestone in Access and our polymer drug delivery Programmes labeled,’said Kerry Grey , President and CEO of Access. ‘As previously reported, preliminary results from in a phase I study which AP5346 in Europe showed that AP5346 was well tolerated and indications from activity. Based on these encouraging results, us follow pursuing extended clinical studies. ‘.. ###Social medical in the 21stAs previously reported AP5346 IND of the for tumors – Access Pharmaceuticals, Inc.